论文信息 - Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. - 字舞流文

Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.

T. Brümmendorf | J. Cortes | M. Deininger | C. Chuah | M. Mauro | E. Leip | C. Gambacorti-Passerini | A. Hochhaus | Dong-Wook Kim | N. Bardy-Bouxin | Laurence Reilly | A. Jeynes-Ellis